← Leaderboards
Thomas S Griffith
Minneapolis Va Medical Center
$6,611,303
Attributed
$6,611,303
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $640.7K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,611,303 · 6
VA$0 · 3
By mechanism
R01$3,874,123 · 2
R35$1,937,083 · 1
R21$426,125 · 1
R56$371,938 · 1
M01$2,034 · 1
IK6$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsImmuneImmune ResponseCessation Of LifeImmune SystemResponseSepsisInfectionMouse ModelAffectSecondary InfectionMortalityFunctional DisorderImmunityCd4 Positive T LymphocytesT-LymphocyteAmericanAcuteCytokineFitnessAdultImmunosuppressionIncidenceEvent
Grant awards (41)
CD4 T cell dysfunction and reprogramming during sepsis$387,500
R35 · FY2025 · GM · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2025 · VA · contact PI
Using microbially-experienced mice to study the innate immune response in sepsis$0
I01 · FY2025 · VA · contact PI
CD4 T cell dysfunction and reprogramming during sepsis$387,500
R35 · FY2024 · GM · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2024 · VA · contact PI
Using microbially-experienced mice to study the innate immune response in sepsis$0
I01 · FY2024 · VA · contact PI
CD4 T cell dysfunction and reprogramming during sepsis$387,500
R35 · FY2023 · GM · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2023 · VA · contact PI
Using microbially-experienced mice to study the innate immune response in sepsis$0
I01 · FY2023 · VA · contact PI
Integrated use of genomics, metabolomics, and cytokine profiling to validate the use of 'dirty' mice to study sepsis pathophysiology$0
I21 · FY2023 · VA · contact PI
CD4 T cell dysfunction and reprogramming during sepsis$387,500
R35 · FY2022 · GM · contact PI
Exploiting microbial exposure to study the immune response to uropathogenic E. coli$193,750
R21 · FY2022 · AI · contact PI
Using microbially-experienced mice to study the innate immune response in sepsis$0
I01 · FY2022 · VA · contact PI
Integrated use of genomics, metabolomics, and cytokine profiling to validate the use of 'dirty' mice to study sepsis pathophysiology$0
I21 · FY2022 · VA · contact PI
CD4 T cell dysfunction and reprogramming during sepsis$387,083
R35 · FY2021 · GM · contact PI
Exploiting microbial exposure to study the immune response to uropathogenic E. coli$232,375
R21 · FY2021 · AI · contact PI
Impairment and recovery of CD4 T cell-dependent B cell responses after sepsis$0
I01 · FY2021 · VA · contact PI
Impairment and recovery of CD4 T cell-dependent B cell responses after sepsis$0
I01 · FY2020 · VA · contact PI
Alterations in CD4 T cells during sepsis$310,131
R01 · FY2019 · GM · contact PI
Impairment and recovery of CD4 T cell-dependent B cell responses after sepsis$0
I01 · FY2019 · VA · contact PI
Alterations in CD4 T cells during sepsis$310,131
R01 · FY2018 · GM · contact PI
Impairment and recovery of CD4 T cell-dependent B cell responses after sepsis$0
I01 · FY2018 · VA · contact PI
Alterations in CD4 T cells during sepsis$312,027
R01 · FY2017 · GM · contact PI
Alterations in CD4 T cells during sepsis$315,934
R01 · FY2016 · GM · contact PI
Suppression of T cell immunity during sepsis$0
I01 · FY2016 · VA · contact PI
Suppression of T cell immunity during sepsis$0
I01 · FY2015 · VA · contact PI
Suppression of T cell immunity during sepsis$0
I01 · FY2014 · VA · contact PI
TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC$242,926
R01 · FY2013 · CA · contact PI
Suppression of T cell immunity during sepsis$0
I01 · FY2013 · VA · contact PI
TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC$258,455
R01 · FY2012 · CA · contact PI
TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC$223,840
R01 · FY2011 · CA · contact PI
TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC$37,003
R01 · FY2011 · CA · contact PI
TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC$268,794
R01 · FY2010 · CA · contact PI
Apoptotic cells induce tolerance through TRAIL-expressing CD8+ regulatory T cells$371,938
R56 · FY2009 · AI · contact PI
TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC$268,794
R01 · FY2009 · CA · contact PI
Recombinant Immunotherapy for Renal Cell Carcinoma$258,035
R01 · FY2008 · CA · contact PI
Recombinant Immunotherapy for Renal Cell Carcinoma$258,035
R01 · FY2007 · CA · contact PI
TRAIL: A MECHANISM FOR BCG-INDUCED ANTI-TUMOR ACTIVITY IN BLADDER CANCER$2,034
M01 · FY2007 · RR · contact PI
Recombinant Immunotherapy for Renal Cell Carcinoma$265,742
R01 · FY2006 · CA · contact PI
Recombinant Immunotherapy for Renal Cell Carcinoma$272,138
R01 · FY2005 · CA
Recombinant Immunotherapy for Renal Cell Carcinoma$272,138
R01 · FY2004 · CA